Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China

By on    Pharma Industry News  

Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China

Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease (TED), has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Drug Administration (NMPA). This marks a significant milestone as IBI311 is the first […]

Amgen seeks European approval for teprotumumab in thyroid eye disease

By on    Pharma Industry News  

Amgen seeks European approval for teprotumumab in thyroid eye disease

Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. This treatment, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), is aimed at adults suffering from moderate to severe Thyroid Eye Disease […]